You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 6, 2024

Claims for Patent: 10,689,346


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,689,346
Title:Human plasma kallikrein inhibitors
Abstract: Disclosed are compounds of formula I ##STR00001## as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
Inventor(s): Kotian; Pravin L. (Hoover, AL), Babu; Yarlagadda S. (Birmingham, AL), Wu; Minwan (Vestavia Hills, AL), Chintareddy; Venkat R. (Vestavia Hills, AL), Kumar; V. Satish (Birmingham, AL), Zhang; Weihe (Vestavia, AL)
Assignee: BioCryst Pharmaceuticals, Inc. (Durham, NC)
Application Number:16/400,798
Patent Claims: 1. A method of treating a disease or condition characterized by unwanted plasma kallikrein activity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula II, or a pharmaceutically acceptable salt thereof: ##STR00585## wherein: X represents CH, C(OH), C(O(C.sub.1-C.sub.6)alkyl), --C(NH.sub.2), --C(NR.sup.aR.sup.b), --C(N.sub.3), --C(CN), --C(NO.sub.2), --C(S(O).sub.nR.sup.a), --C[--C(.dbd.O)R.sup.c], --C[--C(.dbd.O)NR.sup.cR.sup.d], --C[--C(.dbd.O)SR.sup.c], --C[--S(O)R.sup.c], --C[--S(O).sub.2R.sup.c], --C[S(O)(OR.sup.c)], --C[--S(O).sub.2(OR.sup.c)], --C[--SO.sub.2NR.sup.cR.sup.d], --C(halogen), --C[(C.sub.1-C.sub.5)alkyl], --C[(C.sub.4-C.sub.5)carbocyclyl], --C[(C.sub.1-C.sub.8)substituted alkyl], --C[(C.sub.2-C.sub.8)alkenyl], --C[(C.sub.2-C.sub.8)substituted alkenyl], --C[(C.sub.2-C.sub.8)alkynyl], --C[(C.sub.2-C.sub.8)substituted alkynyl], --C[aryl(C.sub.1-C.sub.5)alkyl] or N; --Y--R.sup.4 represents --((C.sub.1-C.sub.6)alkyl)-R.sup.4, --CH.sub.2C(O)--R.sup.4, --CH.sub.2NH-R.sup.4, --CH.sub.2N((C.sub.1-C.sub.6)alkyl)-R.sup.4, --CR.sup.aR.sup.b--R.sup.4, --NH--R.sup.4, --NHCH.sub.2--R.sup.4, --NHC(O)--R.sup.4, --N((C.sub.1-C.sub.6)alkyl)-R.sup.4, --N((C.sub.1-C.sub.6)alkyl)CH.sub.2--R.sup.4, --N((CH.sub.2).sub.2OH)--R.sup.4, --N[(C.sub.3-C.sub.8)cycloalkyl(C.sub.1-C.sub.6)alkyl]R.sup.4, -heterocyclyl-R.sup.4, --OR.sup.4, --OCH.sub.2--R.sup.4, --OC(O)--R.sup.4, --SCH.sub.2R.sup.4, or --SR.sup.4, wherein the (C.sub.1-C.sub.6)alkyl moiety of --((C.sub.1-C.sub.6)alkyl)-R.sup.4 is optionally substituted; Z is absent or represents one or more substituents independently selected from the group consisting of halo, hydroxy, (C.sub.1-C.sub.6)alkyl, --CF.sub.3, --OCF.sub.3, (C.sub.1-C.sub.6)alkoxy, aryl, aryloxy, amino, amino(C.sub.1-C.sub.6)alkyl, --C(O)NH.sub.2, cyano, --NHC(O)(C.sub.1-C.sub.6)alkyl, --SO.sub.2(C.sub.1-C.sub.6)alkyl, --SO.sub.2NH.sub.2, (C.sub.3-C.sub.5)cycloalkyl, (CH.sub.2).sub.rOR.sup.a, N.sub.02, (CH.sub.2).sub.rNR.sup.aR.sup.b, (CH.sub.2).sub.rC(O)R.sup.a, NR.sup.aC(O)R.sup.b, C(O)NR.sup.cR.sup.d, NR.sup.aC(O)NR.sup.cR.sup.d, --C(.dbd.NR.sup.a)NR.sup.cR.sup.d, NHC(.dbd.NR.sup.a)NR.sup.cR.sup.d, NR.sup.aR.sup.b, SO.sub.2NR.sup.cR.sup.d, NR.sup.aSO.sub.2NR.sup.cR.sup.d, NR.sup.aSO.sub.2-(C.sub.1-C.sub.6)alkyl, NR.sup.aSO.sub.2R.sup.a, S(O).sub.pR.sup.a, (CF.sub.2).sub.rCF.sub.3, NHCH.sub.2R.sup.a, OCH.sub.2R.sup.a, SCH.sub.2R.sup.a, NH(CH.sub.2).sub.2(CH.sub.2).sub.rR.sup.a, O(CH.sub.2).sub.2(CH.sub.2).sub.rR.sup.a, and S(CH.sub.2).sub.2(CH.sub.2).sub.rR.sup.a; or alternatively Z is a 5- or 6-membered aromatic heterocycle containing from 1 to 4 heteroatoms selected from the group consisting of N, O, and S; R.sup.1c represents halo, amino(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy, cyano, --C(.dbd.NH)NH.sub.2, --CONR.sup.aR.sup.b, --(C.sub.1-C.sub.6)alkylCONR.sup.aR.sup.b, --SO.sub.2CH.sub.3, formyl, acyl, --NH.sub.2, --C(.dbd.NH)NH(OH), --C(.dbd.NH)NH(C(O)O--(C.sub.1-C.sub.6)alkyl), --C(.dbd.NH)NH(C(O)O--(C.sub.1-C.sub.6)haloalkyl), --C(.dbd.NH)NH(C(O)S--(C.sub.1-C.sub.6)alkyl), --C(.dbd.NH)NH(C(O)(OCH(C.sub.1-C.sub.6)alkyl)OC(O)(C.sub.1-C.sub.6)alkyl- ), optionally substituted aryl, or optionally substituted heteroaryl; R.sup.2 represents halo, (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl, (C.sub.1-C.sub.6)fluoroalkyl, --OCH.sub.3, --Si(CH.sub.3).sub.3, --CONH.sub.2, --C(O)OH, cyano, or phenyl; R.sup.3 represents --NH--, --O--, optionally substituted aryl, heteroaryl, phenyl, carbocyclyl, or heterocyclyl; R.sup.3a is absent or represents one or more substituents independently selected from the group consisting of halo, hydroxy, (C.sub.1-C.sub.6)alkyl, --CF.sub.3, --OCF.sub.3, (C.sub.1-C.sub.6)alkoxy, aryl, aryloxy, amino, amino(C.sub.1-C.sub.6)alkyl, --C(O)NH.sub.2, cyano, --NHC(O)(C.sub.1-C.sub.6)alkyl, --SO.sub.2(C.sub.1-C.sub.6)alkyl, --SO.sub.2NH.sub.2, (C.sub.3-C.sub.8)cycloalkyl, (CH.sub.2).sub.rOR.sup.a, NO.sub.2, (CH.sub.2).sub.rNR.sup.aR.sup.b, (CH.sub.2).sub.rC(O)R.sup.a, NR.sup.aC(O)R.sup.b, C(O)NR.sup.cR.sup.d, NR.sup.aC(O)NR.sup.cR.sup.d, --C(.dbd.NR.sup.a)NR.sup.cR.sup.d, NHC(.dbd.NR.sup.a)NR.sup.cR.sup.d, NR.sup.aR.sup.b, SO.sub.2NR.sup.cR.sup.d, NR.sup.aSO.sub.2NR.sup.cR.sup.d, NR.sup.aSO.sub.2-(C.sub.1-C.sub.6)alkyl, NR.sup.aSO.sub.2R.sup.a, S(O).sub.pR.sup.a, (CF.sub.2).sub.rCF.sub.3, NHCH.sub.2R.sup.a, OCH.sub.2R.sup.a, SCH.sub.2R.sup.a, NH(CH.sub.2).sub.2(CH.sub.2).sub.rR.sup.a, O(CH.sub.2).sub.2(CH.sub.2).sub.rR.sup.a, or S(CH.sub.2).sub.2(CH.sub.2).sub.rR.sup.a; or alternatively R.sup.3a is a 5- or 6-membered aromatic heterocycle containing from 1 to 4 heteroatoms selected from the group consisting of N, O, and S; R.sup.4 represents hydrogen, hydroxy, optionally substituted (C.sub.1-C.sub.6)alkyl, optionally substituted (C.sub.3-C.sub.8)cycloalkyl, heterocyclyl(C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl(C.sub.1-C.sub.6)alkyl, --CH.sub.2OH, --CH((C.sub.1-C.sub.6)alkyl)OH, --CH(NH.sub.2)CH((C.sub.1-C.sub.6)alkyl).sub.2, optionally substituted aryl, optionally substituted aryl(C.sub.1-C.sub.6)alkyl, heteroaryl, optionally substituted heteroaryl(C.sub.1-C.sub.6)alkyl, --CH.sub.2S(C.sub.1-C.sub.6)alkyl, amino, or cyano; each R.sup.a and R.sup.b is independently H, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, (C.sub.3-C.sub.8)carbocyclyl, --C(.dbd.O)R.sup.c, --C(.dbd.O)OR.sup.c, --C(.dbd.O)NR.sup.cR.sup.d, --C(.dbd.O)SR.sup.c, --S(O)R.sup.c, --S(O).sub.2R.sup.c, --S(O)(OR.sup.c), or --SO.sub.2NR.sup.cR.sup.d; each R.sup.c and R.sup.d is independently H, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.4-C.sub.8) carbocyclyl, optionally substituted aryl, optionally substituted heteroaryl, --C(.dbd.O)(C.sub.1-C.sub.8)alkyl, --S(O)n(C.sub.1-C.sub.8)alkyl, or aryl(C.sub.1-C.sub.8)alkyl; or when R and R.sup.d are bonded to a common nitrogen atom, then they may form a 3- to 7-membered heterocyclic ring wherein optionally a carbon atom of said heterocyclic ring may be replaced with --O--, --S-- or --NR.sup.a--; n is 2 or 3; r is independently for each occurrence 0, 1, 2, or 3; p is independently for each occurrence 0, 1, or 2; and the stereochemical configuration at any chiral center is R, S, or a mixture of R and S.

2. The method of claim 1, wherein X represents CH, C(OH), C(O(C.sub.1-C.sub.6)alkyl), --C(NH.sub.2), --C(NR.sup.aR.sup.b), --C(halogen), --C[(C.sub.2-C.sub.8)alkenyl], --C[(C.sub.2-C.sub.8)substituted alkenyl], or N.

3. The method of claim 1, wherein X represents CH.

4. The method of claim 1, wherein --X--Y-- represents --CHNHCH.sub.2--, --C(OH)CH.sub.2CH.sub.2--, or --CHOCH.sub.2--.

5. The method of claim 1, wherein R.sup.3 represents phenylene-R.sup.3a.

6. The method of claim 1, wherein --R.sup.3--R.sup.a represents ##STR00586## ##STR00587##

7. The method of claim 1, wherein R.sup.4 is cyclopropyl.

8. The method of claim 1, wherein R.sup.3 is phenyl, and R.sup.3a is ortho, meta, or para --OH.

9. The method of claim 1, wherein R.sup.3 is phenyl, and R.sup.3a is meta or para --NH.sub.2.

10. The method of claim 1, wherein R.sup.3 is phenyl, and R.sup.3a is meta or para --CN.

11. The method of claim 1, wherein Z is absent, or represents fluoro or chloro.

12. The method of claim 1, wherein Z represents 2-F, 4-F, 5-F, 6-F, 6-Cl, or 5-(C.sub.3-C.sub.8)cycloalkyl.

13. The method of claim 1, wherein R.sup.1c represents aminomethyl.

14. The method of claim 1, wherein R.sup.1c represents cyano.

15. The method of claim 1, wherein R.sup.1c represents --SO.sub.2CH.sub.3.

16. The method of claim 1, wherein R.sup.2 is --CH.sub.3, --CF.sub.3, tert-butyl, cyclopropyl, --OCH.sub.3, --Si(CH.sub.3).sub.3, --CONH.sub.2, cyano, or phenyl.

17. The method of claim 1, wherein the compound of formula (II) is selected from the group consisting of: ##STR00588## ##STR00589## ##STR00590## ##STR00591## ##STR00592## ##STR00593##

18. The method of claim 1, wherein the compound of formula (II) has the structure: ##STR00594##

19. The method of claim 1, wherein the compound of formula (II) is the (+)-enantiomer.

20. The method of claim 18, wherein the compound of formula (II) is the (-)-enantiomer.

21. The method of claim 18, wherein the compound of formula (II) is a hydrochloride salt.

22. The method of claim 18, wherein the compound of formula (II) is a bis(hydrochloride) salt.

23. The method of claim 19, wherein the compound of formula (II) is a hydrochloride salt.

24. The method of claim 19, wherein the compound of formula (II) is a bis(hydrochloride) salt.

25. The method of claim 20, wherein the compound of formula (II) is a hydrochloride salt.

26. The method of claim 20, wherein the compound of formula (II) is a bis(hydrochloride) salt.

27. The method of claim 1, wherein the disease or condition characterized by unwanted plasma kallikrein activity is selected from the group consisting of stroke, inflammation, reperfusion injury, acute myocardial infarction, deep vein thrombosis, post fibrinolytic treatment condition, angina, edema, angioedema, hereditary angioedema, sepsis, arthritis, hemorrhage, blood loss during cardiopulmonary bypass, inflammatory bowel disease, diabetes mellitus, retinopathy, diabetic retinopathy, diabetic macular edema, diabetic macular degeneration, age-related macular edema, age-related macular degeneration, proliferative retinopathy, neuropathy, hypertension, brain edema, increased albumin excretion, macroalbuminuria, and nephropathy.

28. The method of claim 1, wherein the disease or condition characterized by unwanted plasma kallikrein activity is angioedema.

29. The method of claim 1, wherein the disease or condition characterized by unwanted plasma kallikrein activity is hereditary angioedema.

30. The method of claim 18, wherein the disease or condition characterized by unwanted plasma kallikrein activity is selected from the group consisting of stroke, inflammation, reperfusion injury, acute myocardial infarction, deep vein thrombosis, post fibrinolytic treatment condition, angina, edema, angioedema, hereditary angioedema, sepsis, arthritis, hemorrhage, blood loss during cardiopulmonary bypass, inflammatory bowel disease, diabetes mellitus, retinopathy, diabetic retinopathy, diabetic macular edema, diabetic macular degeneration, age-related macular edema, age-related macular degeneration, proliferative retinopathy, neuropathy, hypertension, brain edema, increased albumin excretion, macroalbuminuria, and nephropathy.

31. The method of claim 18, wherein the disease or condition characterized by unwanted plasma kallikrein activity is angioedema.

32. The method of claim 18, wherein the disease or condition characterized by unwanted plasma kallikrein activity is hereditary angioedema.

33. The method of claim 19, wherein the disease or condition characterized by unwanted plasma kallikrein activity is selected from the group consisting of stroke, inflammation, reperfusion injury, acute myocardial infarction, deep vein thrombosis, post fibrinolytic treatment condition, angina, edema, angioedema, hereditary angioedema, sepsis, arthritis, hemorrhage, blood loss during cardiopulmonary bypass, inflammatory bowel disease, diabetes mellitus, retinopathy, diabetic retinopathy, diabetic macular edema, diabetic macular degeneration, age-related macular edema, age-related macular degeneration, proliferative retinopathy, neuropathy, hypertension, brain edema, increased albumin excretion, macroalbuminuria, and nephropathy.

34. The method of claim 19, wherein the disease or condition characterized by unwanted plasma kallikrein activity is angioedema.

35. The method of claim 19, wherein the disease or condition characterized by unwanted plasma kallikrein activity is hereditary angioedema.

36. The method of claim 24, wherein the disease or condition characterized by unwanted plasma kallikrein activity is selected from the group consisting of stroke, inflammation, reperfusion injury, acute myocardial infarction, deep vein thrombosis, post fibrinolytic treatment condition, angina, edema, angioedema, hereditary angioedema, sepsis, arthritis, hemorrhage, blood loss during cardiopulmonary bypass, inflammatory bowel disease, diabetes mellitus, retinopathy, diabetic retinopathy, diabetic macular edema, diabetic macular degeneration, age-related macular edema, age-related macular degeneration, proliferative retinopathy, neuropathy, hypertension, brain edema, increased albumin excretion, macroalbuminuria, and nephropathy.

37. The method of claim 24, wherein the disease or condition characterized by unwanted plasma kallikrein activity is angioedema.

38. The method of claim 24, wherein the disease or condition characterized by unwanted plasma kallikrein activity is hereditary angioedema.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.